Novartis gains FDA approval for Gilenya(TM), a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression Novartis, 22 Sep 2010 Accessed on 4 Jan 2012 from http://www.novartis.com/newsroom/media-releases/en/2010/1445917.shtml.
Sphingosine 1-phosphate (S1P): Physiology and the effects of S1P receptor modulation. Hla T, Brinkmann V Neurology. 2011 Feb 22; 76(8 Suppl 3):S3-8. PMID: 21339489. Abstract
Fingolimod is a potential novel therapy for multiple sclerosis. Aktas O, Küry P, Kieseier B, Hartung H-P Nat Rev Neurol. 2010 Jul; 6(7):373-82. Epub 2010 Jun 15. PMID: 20551946. Abstract
New approaches in the management of multiple sclerosis. Barten LJ, Allington DR, Procacci KA, Rivey MP Drug Des Devel Ther. 2010; 4:343-66. Epub 2010 Nov 24. PMID: 21151622. Abstract
ChemIDplus Advanced United States National Library of Medicine Accessed on 29 Jul 2013 from http://chem.sis.nlm.nih.gov/chemidplus/chemidheavy.jsp. Note: Compound name must be entered under "Substance Identification" and then "Names and Synonyms" selected to view synonyms.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L, Radue E-W, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, et al. N Engl J Med. 2010 Feb 4; 362(5):387-401. Epub 2010 Jan 20. PMID: 20089952. Abstract
FDA approves first oral drug to reduce MS relapses FDA Accessed on 4 Jan 2012 from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm226755.htm.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, et al. N Engl J Med. 2010 Feb 4; 362(5):402-15. Epub 2010 Jan 20. PMID: 20089954. Abstract
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. Webb M, Tham C-S, Lin F-F, Lariosa-Willingham K, Yu N, Hale J, Mandala S, Chun J, Rao TS J Neuroimmunol. 2004 Aug; 153(1-2):108-21. PMID: 15265669. Abstract
Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S, Li X-K J Pharmacol Exp Ther. 2003 Apr; 305(1):70-7. PMID: 12649354. Abstract
Oral fingolimod (FTY720) for relapsing multiple sclerosis. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW, et al. N Engl J Med. 2006 Sep 14; 355(11):1124-40. PMID: 16971719. Abstract
FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM J Immunol. 2000 Jun 1; 164(11):5761-70. PMID: 10820254. Abstract
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Kahan BD, Karlix JL, Ferguson RM, Leichtman AB, Mulgaonkar S, Gonwa TA, Skerjanec A, Schmouder RL, Chodoff L Transplantation. 2003 Oct 15; 76(7):1079-84. PMID: 14557756. Abstract
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Mehling M, Lindberg R, Raulf F, Kuhle J, Hess C, Kappos L, Brinkmann V Neurology. 2010 Aug 3; 75(5):403-10. Epub 2010 Jun 30. PMID: 20592255. Abstract
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class Novartis Accessed on 4 Jan 2012 from http://www.novartis.com/newsroom/media-releases/en/2010/1443688.shtml.
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU Novartis Accessed on 4 Jan 2012 from http://www.novartis.com/newsroom/media-releases/en/2011/1498377.shtml.
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia Novartis Accessed on 4 Jan 2012 from http://www.novartis.is/newsroom/media-releases/en/2011/1481634.shtml.
Gilenya prescribing information Novartis Accessed on 4 Jan 2012 from http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf.
FTY720 in patients with primary progressive multiple sclerosis (INFORMS) ClinicalTrials.gov Accessed on 4 Jan 2012 from http://clinicaltrials.gov/ct2/show/record/NCT00731692.
Efficacy and safety of FTY720 in patients with relapsing multiple sclerosis ClinicalTrials.gov. Accessed on 4 Jan 2012 from http://clinicaltrials.gov/show/NCT00333138.
The immune modulator FTY720 targets sphingosine 1-phosphate receptors. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, et al. J Biol Chem. 2002 Jun 14; 277(24):21453-7. Epub 2002 Apr 19. PMID: 11967257. Abstract
Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. Oo M L, Thangada S, Wu M-T, Liu CH, Macdonald TL, Lynch KR, Lin C-Y, Hla T J Biol Chem. 2007 Mar 23; 282(12):9082-9. Epub 2007 Jan 21. PMID: 17237497. Abstract
FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Brinkmann V Br J Pharmacol. 2009 Nov; 158(5):1173-82. Epub 2009 Oct 08. PMID: 19814729. Abstract
LC-MS/MS determination of FTY720 and FTY720-phosphate in murine intracellular compartments and human plasma. Ferreirós N, Labocha S, Schröder M, Radeke HH, Geisslinger G J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Mar 1; 887-888:122-7. Epub 2012 Jan 30. PMID: 22341683. Abstract
New extension study data with Novartis drug Gilenya® shows patients successfully treated for up to 7 years in relapsing MS Novartis, 19 Apr 2012 Accessed on 16 May 2012 from http://www.novartis.com/newsroom/media-releases/en/2012/1604172.shtml.
Novartis updates US label on Gilenya® following discussions with the FDA Novartis, 20 Apr 2012 Accessed on 16 May 2012 from http://www.novartis.com/newsroom/media-releases/en/2012/1604414.shtml.
Fingolimod-A sphingosine-like molecule inhibits vesicle mobility and secretion in astrocytes. Trkov S, Stenovec M, Kreft M, Potokar M, Parpura V, Davletov B, Zorec R Glia. 2012 May 25. PMID: 22639011. Abstract
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study Novartis, 11 Jun 2012 Accessed on 12 Jun 2012 from http://www.novartis.com/newsroom/media-releases/en/2012/1618585.shtml.
Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results. David OJ, Ocwieja M, Meiser K, Emotte C, Jakab A, Wemer J, den Daas I, Schmouder R Int J Clin Pharmacol Ther. 2012 Jun 26. PMID: 22735460. Abstract
Impact of Fingolimod Therapy on Magnetic Resonance Imaging Outcomes in Patients With Multiple SclerosisImpact of Fingolimod Therapy in Multiple Sclerosis. Radue E-W, O'Connor P, Polman CH, Hohlfeld R, Calabresi P, Selmaj K, Mueller-Lenke N, Agoropoulou C, Holdbrook F, de Vera A, et al. Arch Neurol. 2012 Jul 2:1-11. PMID: 22751847. Abstract
Fingolimod Impedes Schwann Cell-Mediated Myelination: Implications for the Treatment of Immune Neuropathies?Effect of Fingolimod on Schwann Cells. Köhne A, Stettner M, Jangouk P, Dehmel T, Hartung H-P, Lehmann HC, Kieseier BC Arch Neurol. 2012 Jul 2:1-10. PMID: 22751954. Abstract
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis. Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A Eur J Clin Pharmacol. 2012 Apr; 68(4):441-8. Epub 2011 Nov 05. PMID: 22057838. Abstract
Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. van Doorn R, Nijland PG, Dekker N, Witte ME, Lopes-Pinheiro MA, van Het Hof B, Kooij G, Reijerkerk A, Dijkstra C, van van der Valk P, et al. Acta Neuropathol. 2012 Jul 19. Epub 2012 Jul 19. PMID: 22810490. Abstract
Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases. Hakiki B, Portaccio E, Giannini M, Razzolini L, Pastò L, Amato M P Mult Scler. 2012 Jul 24. PMID: 22829326. Abstract
Editors' Pick Fingolimod, a sphingosine-1 phosphate receptor modulator, increases BDNF levels and improves symptoms of a mouse model of Rett syndrome. Deogracias R, Yazdani M, Dekkers MPJ, Guy J, Ionescu M CS, Vogt KE, Barde Y-A Proc Natl Acad Sci U S A. 2012 Aug 28; 109(35):14230-5. Epub 2012 Aug 13. PMID: 22891354. Abstract
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain. Cannon RE, Peart JC, Hawkins BT, Campos CR, Miller DS Proc Natl Acad Sci U S A. 2012 Sep 4. PMID: 22949658. Abstract
FTY720 mediates activation suppression and G(0)/G (1) cell cycle arrest in a concanavalin A-induced mouse lymphocyte pan-activation model. Zeng X, Wang T, Zhu C, Ye Y, Song B, Lai X, Zeng Y Inflamm Res. 2012 Jun; 61(6):623-34. Epub 2012 Mar 10. PMID: 22407397. Abstract
Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model. Gao F, Liu Y, Li X, Wang Y, Wei D, Jiang W Pharmacol Biochem Behav. 2012 Aug 31; 103(2):187-196. PMID: 22960129. Abstract
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod. Roskell NS, Zimovetz EA, Rycroft CE, Eckert BJ, Tyas DA Curr Med Res Opin. 2012 May; 28(5):767-80. Epub 2012 Apr 24. PMID: 22462530. Abstract
Varicella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimod. Ratchford JN, Costello K, Reich DS, Calabresi PA Neurology. 2012 Oct 3. PMID: 23035072. Abstract
Multiple sclerosis rebound following herpes zoster infection and suspension of fingolimod. Gross C M, Baumgartner A, Rauer S, Stich O Neurology. 2012 Oct 3. PMID: 23035074. Abstract
New analysis indicates that Novartis drug Gilenya shows significant early effect on reducing brain volume loss at 6 months Novartis, 12 Oct 2012 Accessed on 16 Oct 2012 from http://www.novartis.com/newsroom/media-releases/en/2012/1648172.shtml.
Efficacy and safety of fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis (FREEDOMS II) ClinicalTrials.gov, 2 Aug 2012 Accessed on 16 Oct 2012 from http://clinicaltrials.gov/ct2/show/results/NCT00355134.
Early bilateral cystoid macular oedema secondary to fingolimod in multiple sclerosis. Liu L, Cuthbertson F Case Report Med. 2012; 2012:134636. Epub 2012 Sep 13. PMID: 23056052. Abstract
Fingolimod protects cultured cortical neurons against excitotoxic death. Di Menna L, Molinaro G, Di Nuzzo L, Riozzi B, Zappulla C, Pozzilli C, Turrini R, Caraci F, Copani A, Battaglia G, et al. Pharmacol Res. 2012 Oct 13. PMID: 23073075. Abstract
Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P Mult Scler. 2012 Nov; 18(11):1640-3. PMID: 23100526. Abstract
Fingolimod treatment in multiple sclerosis leads to increased macular volume. Nolan R, Gelfand JM, Green AJ Neurology. 2012 Dec 5. PMID: 23223539. Abstract
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis. Havla J, Tackenberg B, Hellwig K, Meinl I, Krumbholz M, Seitz F, Eienbröker C, Gold R, Hohlfeld R, Kleiter I, et al. J Neurol. 2012 Dec 25. Epub 2012 Dec 25. PMID: 23266894. Abstract
Cystoid macular edema associated with fingolimod use for multiple sclerosis. Afshar AR, Fernandes JK, Patel RD, Ksiazek SM, Sheth VS, Reder AT, Hariprasad SM JAMA Ophthalmol. 2013 Jan 1; 131(1):103-7. PMID: 23307220. Abstract
Switching from natalizumab to fingolimod: an observational study. Sempere AP, Martín-Medina P, Berenguer-Ruiz L, Pérez-Carmona N, Sanchez-Perez R, Polache-Vengud J, Feliu-Rey E Acta Neurol Scand. 2013 Jan 22. PMID: 23336398. Abstract
Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia. Wallington-Beddoe CT, Don AS, Hewson J, Qiao Q, Papa RA, Lock RB, Bradstock KF, Bendall LJ PLoS One. 2012; 7(5):e36429. Epub 2012 May 03. PMID: 22570713. Abstract
Sphingosine-1-Phosphate Links Persistent STAT3 Activation, Chronic Intestinal Inflammation, and Development of Colitis-Associated Cancer. Liang J, Nagahashi M, Kim EY, Harikumar KB, Yamada A, Huang W-C, Hait NC, Allegood JC, Price MM, Avni D, et al. Cancer Cell. 2013 Jan 14; 23(1):107-20. Epub 2012 Dec 27. PMID: 23273921. Abstract
Implications of Real-world Adherence on Cost-effectiveness Analysis in Multiple Sclerosis. J Med Econ. 2013 Feb 7. PMID: 23391123. Abstract
Fingolimod phosphate promotes the neuroprotective effects of microglia. Noda H, Takeuchi H, Mizuno T, Suzumura A J Neuroimmunol. 2013 Jan 3. PMID: 23290828. Abstract
FDA approves clinical trial of TDI-132 (Gilenya) in ALS patients ALS Therapy Development Institute, 11 Feb 2013 Accessed on 18 Feb 2013 from http://www.als.net/TDI-132/?f=hr.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data. Mandel M, Mercier F, Eckert B, Chin P, Betensky RA Biometrics. 2013 Feb 14. PMID: 23410536. Abstract
FTY720 (Fingolimod) Attenuates Beta-amyloid Peptide (Aβ(42))-Induced Impairment of Spatial Learning and Memory in Rats. Asle-Rousta M, Kolahdooz Z, Oryan S, Ahmadiani A, Dargahi L J Mol Neurosci. 2013 Feb 26. Epub 2013 Feb 26. PMID: 23435938. Abstract
The role of natural killer cells in multiple sclerosis and their therapeutic implications. Chanvillard C, Jacolik RF, Infante-Duarte C, Nayak RC Front Immunol. 2013; 4:63. Epub 2013 Mar 13. PMID: 23493880. Abstract
New analysis shows Novartis drug Gilenya® significantly reduced rate of brain volume loss across three large Phase III studies Novartis, 21 Mar 2013 Accessed on 25 Mar 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1686799.shtml.
Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation. Wu C, Leong SY, Moore CS, Cui Q L, Gris P, Bernier L-P, Johnson TA, Séguéla P, Kennedy TE, Bar-Or A, et al. J Neuroinflammation. 2013 Mar 19; 10(1):41. Epub 2013 Mar 19. PMID: 23509960. Abstract
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis. Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, Tang D, Zhang X Ophthalmology. 2013 Mar 23. PMID: 23531349. Abstract
Fingolimod Phosphate Attenuates Oligomeric Amyloid β-Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons. Doi Y, Takeuchi H, Horiuchi H, Hanyu T, Kawanokuchi J, Jin S, Parajuli B, Sonobe Y, Mizuno T, Suzumura A PLoS One. 2013; 8(4):e61988. Epub 2013 Apr 12. PMID: 23593505. Abstract
Suppression of Experimental Autoimmune Optic Neuritis by the Novel Agent Fingolimod. An X, Kezuka T, Usui Y, Matsunaga Y, Matsuda R, Yamakawa N, Goto H J Neuroophthalmol. 2013 Apr 19. PMID: 23609767. Abstract
Editors' Pick Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. Cohen JA, Barkhof F, Comi G, Izquierdo G, Khatri B, Montalban X, Pelletier J, Eckert B, Häring DA, Francis G J Neurol. 2013 Apr 30. PMID: 23632946. Abstract
Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient. Piscolla E, Hakiki B, Pastò L, Razzolini L, Portaccio E, Amato MP J Neurol. 2013 May 5. PMID: 23645219. Abstract
Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for relapsing multiple sclerosis: EPOC study rationale and design. Cascione M, Wynn D, Barbato LM, Pestreich L, Schofield L, McCague K J Med Econ. 2013 May 20. PMID: 23647445. Abstract
Fingolimod Modulates Peripheral Effector and Regulatory T Cells in MS Patients. Serpero LD, Filaci G, Parodi A, Battaglia F, Kalli F, Brogi D, Mancardi G L, Uccelli A, Fenoglio D J Neuroimmune Pharmacol. 2013 May 7. Epub 2013 May 07. PMID: 23649711. Abstract
Evaluation of efficacy, safety and tolerability of fingolimod in patients with the relapsing form of multiple sclerosis - 12-month observation. A preliminary report. Maciejek Z, Wójcik-Drączkowska H, Wawrzyniak S, Niezgodzińska-Maciejek A Neurol Neurochir Pol. 2013; 47(2):145-151. PMID: 23650003. Abstract
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons. Takasugi N, Sasaki T, Ebinuma I, Osawa S, Isshiki H, Takeo K, Tomita T, Iwatsubo T PLoS One. 2013; 8(5):e64050. Epub 2013 May 07. PMID: 23667698. Abstract
Relapsing MS patients more satisfied with Novartis oral drug Gilenya(TM) than standard injectable therapies, according to new study results at CMSC Market Watch, The Wall Street Journal, 30 May 2013 Accessed on 31 May 2013 from http://www.marketwatch.com/story/relapsing-ms-patients-more-satisfied-with-novartis-oral-drug-gilenya-than-standard-injectable-therapies-according-to-new-study-results-at-cmsc-2013-05-30.
T-cell response against varicella-zoster virus in fingolimod-treated MS patients. Ricklin ME, Lorscheider J, Waschbisch A, Paroz C, Mehta SK, Pierson DL, Kuhle J, Fischer-Barnicol B, Sprenger T, Lindberg RLP, et al. Neurology. 2013 May 22. PMID: 23700335. Abstract
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis Novartis, 5 Jun 2013 Accessed on 8 Jun 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1707070.shtml.
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis. Campbell JD, McQueen BR, Miravalle A, Corboy JR, Ackermann RT, Vollmer TL, Nair K Am J Manag Care. 2013; 19(4):278-85. PMID: 23725360. Abstract
Switching to Gilenya® (fingolimod) from a standard interferon offers sustained freedom from disease activity for people with relapsing remitting multiple sclerosis Pharmiweb, 10 Jun 2013 Accessed on 20 Jun 2013 from http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=75633#.UcNxHo6-K4k.
Neurorestorative effect of FTY720 in a rat model of Alzheimer's disease: Comparison with Memantine. Hemmati F, Dargahi L, Nasoohi S, Omidbakhsh R, Mohamed Z, Chik Z, Naidu M, Ahmadiani A Behav Brain Res. 2013 Jun 15. PMID: 23777795. Abstract
FTY720 preserved islet β-cell mass by inhibiting apoptosis and increasing survival of β-cells in db/db mice. Moon H, Chon J, Joo J, Kim D, In J, Lee H, Park J, Choi J Diabetes Metab Res Rev. 2013 Jan; 29(1):19-24. PMID: 22936676. Abstract
Severe auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patient. Lysandropoulos AP, Benghiat F Mult Scler. 2013 Jul 1. PMID: 23817558. Abstract
Fingolimod Therapy and Macular Hemorrhage. Bhatti TM, Freedman MS, Mahmoud TH J Neuroophthalmol. 2013 Jul 10. PMID: 23845997. Abstract
Rebound of disease activity during pregnancy after withdrawal of fingolimod. Sempere AP, Berenguer-Ruiz L, Feliu-Rey E Eur J Neurol. 2013 Aug; 20(8):e109-10. PMID: 23829238. Abstract
Homing frequency of human T cells inferred from peripheral blood depletion kinetics after sphingosine-1-phosphate receptor blockade. Mehling M, Brinkmann V, Burgener A-V, Gubser P, Luster AD, Kappos L, Hess C J Allergy Clin Immunol. 2013 May; 131(5):1440-3.e7. Epub 2013 Feb 21. PMID: 23434284. Abstract
Tumefactive multiple sclerosis lesions under fingolimod treatment. Kinney MO, McDonnell G, Wattjes MP, Visser F, van Oosten BW Neurology. 2013 Jul 23; 81(4):403. PMID: 23877798. Abstract
Management of fingolimod-associated macular edema. Chui J, Herkes GK, Chang A JAMA Ophthalmol. 2013 May; 131(5):694-6. PMID: 23538612. Abstract
Patient taking Novartis MS pill developed rare disease Reuters, 30 Jul 2013 Accessed on 8 Aug 2013 from http://www.reuters.com/article/2013/07/30/novartis-gilenya-idUSL6N0G02A520130730.
A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Matsuoka Y, Nagahara Y, Ikekita M, Shinomiya T Br J Pharmacol. 2003 Apr; 138(7):1303-12. PMID: 12711631. Abstract
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies. Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld A K, Van Brocklyn JR, Briesewitz R, Saddoughi SA, et al. Blood. 2013 Aug 7. PMID: 23926298. Abstract
Editors' Pick A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis. Hadjigeorgiou GM, Doxani C, Miligkos M, Ziakas P, Bakalos G, Papadimitriou D, Mprotsis T, Grigoriadis N, Zintzaras E J Clin Pharm Ther. 2013 Aug 20. PMID: 23957759. Abstract
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Francis G, Kappos L, O'Connor P, Collins W, Tang D, Mercier F, Cohen JA Mult Scler. 2013 Aug 15. PMID: 23950550. Abstract
Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use. Minuk A, Belliveau MJ, Almeida DRP, Dorrepaal SJ, Gale JS JAMA Ophthalmol. 2013 Jun; 131(6):802-4. PMID: 23599188. Abstract
Editors' Pick Sphingosine and FTY720 are potent inhibitors of the transient receptor potential melastatin 7 (TRPM7) channels. Qin X, Yue Z, Sun B, Yang W, Xie J, Ni E, Feng Y, Mahmood R, Zhang Y, Yue L Br J Pharmacol. 2013 Mar; 168(6):1294-312. Epub 1969 Dec 31. PMID: 23145923. Abstract
Prolonged and symptomatic bradycardia following a single dose of fingolimod. Faber H, Fischer H-J, Weber F Mult Scler. 2013 Jan; 19(1):126-8. Epub 2012 Jun 22. PMID: 22729989. Abstract
FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod) US Food and Drug Administration, 29 Aug 2013 Accessed on 13 Sep 2013 from http://www.fda.gov/Drugs/DrugSafety/ucm366529.htm.
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation. Lukas S, Patnaude L, Haxhinasto S, Slavin A, Hill-Drzewi M, Horan J, Modis L K J Biomol Screen. 2013 Sep 3. PMID: 24003058. Abstract
A novel immunomodulator, FTY-720 reverses existing cardiac hypertrophy and fibrosis from pressure overload by targeting NFAT (nuclear factor of activated T-cells) signaling and periostin. Liu W, Zi M, Tsui H, Chowdhury SK, Zeef L, Meng Q-J, Travis M, Prehar S, Berry A, Hanley NA, et al. Circ Heart Fail. 2013 Jul; 6(4):833-44. Epub 2013 Jun 10. PMID: 23753531. Abstract
FTY720 inhibits tumor growth and enhances the tumor-suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway. Li M-H, Hla T, Ferrer F Pediatr Blood Cancer. 2013 Sep; 60(9):1418-23. Epub 2013 May 23. PMID: 23704073. Abstract
Editors' Pick Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla A, Karkare SU, Balderston McGuiness C, Korn JR Curr Med Res Opin. 2013 Oct 1. Epub 1969 Dec 31. PMID: 24059944. Abstract
New data show Novartis' Gilenya® reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients Novartis, 4 Oct 2013 Accessed on 4 Oct 2013 from http://www.novartis.com/newsroom/media-releases/en/2013/1733406.shtml.
Shorter washout reduces MS relapse switching off natalizumab Hughes S, Medscape, 7 Oct 2013 Accessed on 10 Oct 2013 from http://www.medscape.com/viewarticle/812174.
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study. Agashivala N, Wu N, Abouzaid S, Wu Y, Kim E, Boulanger L, Brandes DW BMC Neurol. 2013 Oct 4; 13(1):138. Epub 2013 Oct 04. PMID: 24093542. Abstract
Basis for fluctuations in lymphocyte counts in fingolimod-treated patients with multiple sclerosis. Henault D, Galleguillos L, Moore C, Johnson T, Bar-Or A, Antel J Neurology. 2013 Oct 16. PMID: 24132373. Abstract
Deliberate Fingolimod Overdose Presenting with Delayed Hypotension and Bradycardia Responsive to Atropine. Stephenson M, Wong A, Rotella JA, Crump N, Kerr F, Greene SL J Med Toxicol. 2013 Nov 1. PMID: 24178903. Abstract
Recurrent Varicella following Steroids and Fingolimod in a Multiple Sclerosis Patient. Ferraro D, De Biasi S, Vitetta F, Simone A, Federzoni L, Borghi V, Cossarizza A, Nichelli P, Sola P J Neuroimmune Pharmacol. 2013 Oct 27. Epub 2013 Oct 27. PMID: 24163092. Abstract
S1P1 receptor subtype inhibits demyelination and regulates chemokine release in cerebellar slice cultures. Sheridan GK, Dev KK Glia. 2012 Mar; 60(3):382-92. Epub 2011 Nov 22. PMID: 22108845. Abstract
Editors' Pick Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M, Fox RJ, Havrdova E, Kurukulasuriya NC, Sarda SP, Agarwal S, Siddiqui M K, Taneja A, Deniz B Curr Med Res Opin. 2013 Nov 7. Epub 1969 Dec 31. PMID: 24195574. Abstract
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L, For the FIRST Study Investigators J Neurol. 2013 Nov 13. Epub 2013 Nov 13. PMID: 24221641. Abstract
Cystoid macular oedema after fingolimod treatment in multiple sclerosis. Asensio-Sánchez VM, Trujillo-Guzmán L, Ramoa-Osorio R Arch Soc Esp Oftalmol. 2012 Oct 17. PMID: 24269406. Abstract
Fingolimod (FTY720) stimulates ca(2+)/calcineurin signaling in fission yeast. Hagihara K, Kita A, Mizukura A, Yao M, Kitai Y, Kunoh T, Masuko T, Matzno S, Chiba K, Sugiura R PLoS One. 2013; 8(12):e81907. Epub 2013 Dec 03. PMID: 24312601. Abstract
FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. Di Pardo A, Amico E, Favellato M, Castrataro R, Fucile S, Squitieri F, Maglione V Hum Mol Genet. 2013 Dec 18. Epub 2013 Dec 02. PMID: 24301680. Abstract
Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis. Izquierdo G, O'Connor P, Montalban X, von Rosenstiel P, Cremer M, de Vera A, Sfikas N, Francis G, Radue E, Kappos L Mult Scler. 2013 Nov 30. PMID: 24293455. Abstract
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D Curr Med Res Opin. 2013 Dec 5. PMID: 24289170. Abstract
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? Maillart E, Louapre C, Lubetzki C, Papeix C Mult Scler. 2013 Dec 23. PMID: 24367037. Abstract
Tumefactive MS lesions under fingolimod: A case report and literature review. Pilz G, Harrer A, Wipfler P, Oppermann K, Sellner J, Fazekas F, Trinka E, Kraus J Neurology. 2013 Oct 4. PMID: 24097813. Abstract
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model. Anthony DC, Sibson NR, Losey P, Meier D P, Leppert D Neuropharmacology. 2014 Jan 9. PMID: 24412675. Abstract
A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, Tang D, Zhang-Auberson L, Kira J Mult Scler. 2012 Sep; 18(9):1269-77. Epub 2012 Feb 21. PMID: 22354739. Abstract
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. Kira J-I, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, Tsumiyama I, von Rosenstiel P, Zhang-Auberson L, Saida T BMC Neurol. 2014; 14(1):21. Epub 2014 Jan 29. PMID: 24475777. Abstract
Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen JA, Kappos L, Collins W Neurology. 2014 Jan 24. PMID: 24463630. Abstract
Differential effects of fingolimod on B-cell populations in multiple sclerosis. Nakamura M, Matsuoka T, Chihara N, Miyake S, Sato W, Araki M, Okamoto T, Lin Y, Ogawa M, Murata M, et al. Mult Scler. 2014 Feb 18. Epub 2014 Feb 13. PMID: 24526661. Abstract
Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment. Rolf L, Muris A-H, Damoiseaux J, van Daele M, Hupperts R Neurology. 2014 Feb 12. PMID: 24523479. Abstract
Editors' Pick Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study. Bergvall N, Makin C, Lahoz R, Agashivala N, Pradhan A, Capkun G, Petrilla AA, Karkare SU, Balderston McGuiness C, Korn JR PLoS One. 2014; 9(2):e88472. Epub 2014 Feb 06. PMID: 24516663. Abstract
Fingolimod-associated amenorrhea: a report of three cases. Alroughani R Mult Scler. 2014 Feb 10. PMID: 24515730. Abstract
Mapi Pharma granted United States patent covering the process for the preparation of fingolimod for multiple sclerosis Market Watch, The Wall Street Journal, 18 Feb 2014 Accessed on 20 Feb 2014 from http://www.marketwatch.com/story/mapi-pharma-granted-united-states-patent-covering-the-process-for-the-preparation-of-fingolimod-for-multiple-sclerosis-2014-02-18?reflink=MW_news_stmp.
Immune cell trafficking from the brain maintains CNS immune tolerance. Mohammad MG, Tsai VWW, Ruitenberg MJ, Hassanpour M, Li H, Hart PH, Breit SN, Sawchenko PE, Brown DA J Clin Invest. 2014 Mar 3; 124(3):1228-41. Epub 2014 Feb 24. PMID: 24569378. Abstract
Editors' Pick Switching From Natalizumab to Fingolimod in Multiple Sclerosis: A French Prospective Study. Cohen M, Maillart E, Tourbah A, De Sèze J, Vukusic S, Brassat D, Anne O, Wiertlewski S, Camu W, Courtois S, et al. JAMA Neurol. 2014 Feb 24. Epub 1969 Dec 31. PMID: 24566807. Abstract
Fingolimod after natalizumab and the risk of short-term relapse. Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, Lechner-Scott J, Lugaresi A, Duquette P, Girard M, et al. Neurology. 2014 Mar 7. PMID: 24610329. Abstract
Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations. Miyazaki Y, Niino M, Fukazawa T, Takahashi E, Nonaka T, Amino I, Tashiro J, Minami N, Fujiki N, Doi S, et al. Clin Immunol. 2014 Feb 14; 151(2):127-135. PMID: 24607506. Abstract
Use of fingolimod in patients with relapsing remitting multiple sclerosis in Kuwait. Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J Clin Neurol Neurosurg. 2014 Apr; 119:17-20. Epub 2014 Jan 21. PMID: 24635919. Abstract
Successful treatment of fingolimod-associated macular edema with intravitreal triamcinolone with continued fingolimod use. Thoo S, Cugati S, Lee A, Chen C Mult Scler. 2014 Apr 2. PMID: 24696055. Abstract
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. Laroni A, Brogi D, Brescia Morra V, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, et al. BMC Neurol. 2014 Apr 1; 14(1):65. Epub 2014 Apr 01. PMID: 24690227. Abstract
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Calabresi PA, Radue E-W, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, et al. Lancet Neurol. 2014 Mar 27. PMID: 24685276. Abstract
Fingolimod Therapy in Early Multiple Sclerosis: An Efficacy Analysis of the TRANSFORMS and FREEDOMS Studies by Time Since First Symptom. Agius M, Meng X, Chin P, Grinspan A, Hashmonay R CNS Neurosci Ther. 2014 Mar 31. PMID: 24684973. Abstract
Editors' Pick FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway. Ntranos A, Hall O, Robinson DP, Grishkan IV, Schott JT, Tosi DM, Klein SL, Calabresi PA, Gocke AR J Neuroimmunol. 2014 Mar 11. Epub 1969 Dec 31. PMID: 24680062. Abstract
Treatment with the Immunomodulator FTY720 (Fingolimod) Significantly Reduces Renal Inflammation in Murine Unilateral Ureteral Obstruction. Thangada S, Shapiro LH, Silva C, Yamase H, Hla T, Ferrer FA J Urol. 2014 Mar 25. PMID: 24679864. Abstract
Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment. Fukumoto K, Mizoguchi H, Takeuchi H, Horiuchi H, Kawanokuchi J, Jin S, Mizuno T, Suzumura A Behav Brain Res. 2014 Jul 15; 268:88-93. Epub 2014 Apr 05. PMID: 24713151. Abstract
FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system. Pereira FV, Arruda DC, Figueiredo CR, Massaoka MH, Matsuo AL, Bueno V, Rodrigues EG Clinics (Sao Paulo). 2013 Jul; 68(7):1018-27. PMID: 23917669. Abstract
Editors' Pick Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Lahoz R, Reynolds T, Korn JR Curr Med Res Opin. 2014 May 2. PMID: 24754349. Abstract
A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya® (PASSOS) ClinicalTrials.gov, 25 Feb 2014 Accessed on 15 May 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01705236.
The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple scl Barkhof F, de Jong R, Sfikas N, de Vera A, Francis G, Cohen J, on behalf of the TRANSFORMS study group Mult Scler. 2014 May 8. PMID: 24812043. Abstract
Role of p38MAPK in S1P receptor-mediated differentiation of human oligodendrocyte progenitors. Cui Q L, Fang J, Kennedy TE, Almazan G, Antel JP Glia. 2014 May 9. PMID: 24810969. Abstract
New data at AAN to confirm efficacy of Novartis' Gilenya® across four key measures of MS disease activity, including brain volume loss GlobeNewswire, 23 Apr 2014 Accessed on 17 May 2014 from http://www.nasdaq.com/press-release/new-data-at-aan-to-confirm-efficacy-of-novartis-gilenya-across-four-key-measures-of-ms-disease-20140423-00020.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis ClinicalTrials.gov, 6 May 2014 Accessed on 17 May 2014 from http://www.clinicaltrials.gov/ct2/show/NCT01892722.
Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. Baldi E, Guareschi A, Vitetta F, Senesi C, Curti E, Montepietra S, Simone A M, Immovilli P, Caniatti L, Tola M R, et al. Curr Med Res Opin. 2014 May 28:1-7. PMID: 24831186. Abstract
Novartis: CHMP Issues Positive Opinion To Expand EU Label For Gilenya In RRMS RTT News, 29 Apr 2014 Accessed on 19 May 2014 from http://www.rttnews.com/2309584/novartis-chmp-issues-positive-opinion-to-expand-eu-label-for-gilenya-in-rrms.aspx?type=qf&utm_source=google&utm_campaign=sitemap.
An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ Mult Scler. 2014 May 22. PMID: 24852928. Abstract
Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations. Sheridan GK, Dev KK Sci Rep. 2014; 4:5051. PMID: 24851861. Abstract
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod. Hoepner R, Havla J, Eienbröker C, Tackenberg B, Hellwig K, Meinl I, Hohlfeld R, Gold R, Kümpfel T, Kleiter I Mult Scler. 2014 May 19. PMID: 24842961. Abstract
Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis. van Rossum J, Looysen E, Daniels J, Killestein J Mult Scler. 2014 May 27. PMID: 24866203. Abstract
Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory. Hait NC, Wise LE, Allegood JC, O'Brien M, Avni D, Reeves TM, Knapp PE, Lu J, Luo C, Miles MF, et al. Nat Neurosci. 2014 Jul; 17(7):971-80. Epub 2014 May 25. PMID: 24859201. Abstract
FTY720 protects neuronal cells from damage induced by human prion protein by inactivating the JNK pathway. Moon M-H, Jeong J-K, Lee Y-J, Park S-Y Int J Mol Med. 2013 Dec; 32(6):1387-93. Epub 2013 Oct 16. PMID: 24142108. Abstract
Fingolimod (Gilenya) licence extended MS Trust, 12 Jun 2014 Accessed on 12 Jun 2014 from http://www.mstrust.org.uk/news/article.jsp?id=6381.
Fingolimod attenuates splenocyte-induced demyelination in cerebellar slice cultures. Pritchard AJ, Mir AK, Dev KK PLoS One. 2014; 9(6):e99444. Epub 2014 Jun 09. PMID: 24911000. Abstract
Remission with fingolimod in a case of demyelinating polyneuropathy. Erdener SE, Nurlu G, Göçmen R, Erdem-Özdamar S, Tuncer Kurne A Muscle Nerve. 2014 Jun 7. PMID: 24909140. Abstract
Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease. Thomas K, Schrötter H, Halank M, Ziemssen T BMC Neurol. 2014; 14(1):126. Epub 2014 Jun 07. PMID: 24906818. Abstract
Effects of vitamin d3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. Al-Jaderi Z, Maghazachi AA Toxins (Basel). 2013; 5(11):1932-47. PMID: 24169587. Abstract
The autonomic balance predicts cardiac responses after the first dose of fingolimod. Rossi S, Rocchi C, Studer V, Motta C, Lauretti B, Germani G, Macchiarulo G, Marfia G, Centonze D Mult Scler. 2014 Jun 23. PMID: 24957049. Abstract
Fingolimod (Gilenya) eligibility extended by NHS England MS Trust, 2 July 2014 Accessed on 3 July 2014 from http://www.mstrust.org.uk/news/article.jsp?id=6400.
Effect of fingolimod (FTY720) on cerebral blood flow, platelet function, and macular thickness in healthy volunteers. Ocwieja M, Meiser K, David OJ, Valencia J, Wagner F, Schreiber SJ, Pleyer U, Ziemer S, Schmouder R Br J Clin Pharmacol. 2014 Jun 29. PMID: 24976291. Abstract
Real-World Use of Fingolimod in Patients with Relapsing Remitting Multiple Sclerosis: A Retrospective Study Using the National Multiple Sclerosis Registry in Kuwait. Al-Hashel J, Ahmed SF, Behbehani R, Alroughani R CNS Drugs. 2014 Jul 11. PMID: 25011422. Abstract
Fingolimod for the Treatment of Intracerebral Hemorrhage: A 2-Arm Proof-of-Concept Study. Fu Y, Hao J, Zhang N, Ren L, Sun N, Li Y-J, Yan Y, Huang D, Yu C, Shi F-D JAMA Neurol. 2014 Jul 7. PMID: 25003359. Abstract
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy. Hellmann MA, Lev N, Lotan I, Mosberg-Galili R, Inbar E, Luckman J, Fichman-Horn S, Yakimov M, Steiner I J Neurol Sci. 2014 Jun 17. PMID: 25001515. Abstract
Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis. Bergvall N, Petrilla AA, Karkare SU, Lahoz R, Agashivala N, Pradhan A, Capkun G, Makin C, Balderston McGuiness C, Korn JR J Med Econ. 2014 Jul 23:1-12. PMID: 25019581. Abstract
Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod. Correale J, Chiquete E, Milojevic S, Frider N, Bajusz I Drug Des Devel Ther. 2014; 8:859-67. Epub 2014 Jun 25. PMID: 25028537. Abstract
Oral fingolimod reduces glutamate-mediated intracortical excitability in relapsing-remitting multiple sclerosis. Landi D, Vollaro S, Pellegrino G, Mulas D, Ghazaryan A, Falato E, Pasqualetti P, Rossini P, Filippi M Clin Neurophysiol. 2014 Jun 19. PMID: 25022794. Abstract
The Development and Maintenance of Paclitaxel-Induced Neuropathic Pain Requires Activation of the Sphingosine 1-Phosphate Receptor Subtype 1. Janes K, Little JW, Li C, Bryant L, Chen C, Chen Z, Kamocki K, Doyle T, Snider A, Esposito E, et al. J Biol Chem. 2014 May 29. PMID: 24876379. Abstract
Frequency and economic impact of comorbid cardiac conditions with multiple sclerosis. Franklin MA, Happe LE, Dillman R, Marshall LZ J Manag Care Pharm. 2014 Aug; 20(8):795-9. PMID: 25062072. Abstract
Life-threatening asthma attack during prolonged fingolimod treatment: case report. Zecca C, Caporro M, Györik S, Gobbi C Patient Prefer Adherence. 2014; 8:987-9. Epub 2014 Jul 14. PMID: 25053881. Abstract
FTY720 induces apoptosis of m2 subtype acute myeloid leukemia cells by targeting sphingolipid metabolism and increasing endogenous ceramide levels. Chen L, Luo L-F, Lu J, Li L, Liu Y-F, Wang J, Liu H, Song H, Jiang H, Chen S-J, et al. PLoS One. 2014; 9(7):e103033. Epub 2014 Jul 22. PMID: 25050888. Abstract
Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Colombo E, Di Dario M, Capitolo E, Chaabane L, Newcombe J, Martino G, Farina C Ann Neurol. 2014 Jul 4. PMID: 25043204. Abstract
Fingolimod affects gene expression profile associated with LPS-induced memory impairment. Omidbakhsh R, Rajabli B, Nasoohi S, Khallaghi B, Mohamed Z, Naidu M, Ahmadiani A, Dargahi L Exp Brain Res. 2014 Aug 7. Epub 2014 Aug 07. PMID: 25098558. Abstract
Fingolimod in active multiple sclerosis: an impressive decrease in Gd-enhancing lesions. Muris A-H, Rolf L, Damoiseaux J, Koeman E, Hupperts R BMC Neurol. 2014 Aug 20; 14(1):164. Epub 2014 Aug 20. PMID: 25138918. Abstract
FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. Blanc CA, Rosen H, Lane TE J Neuroinflammation. 2014 Aug 20; 11(1):138. Epub 2014 Aug 20. PMID: 25138356. Abstract
Intermittent Atrioventricular Block following Fingolimod Initiation. Gialafos E, Gerakoulis S, Grigoriou A, Haina V, Kilidireas C, Stamboulis E, Andreadou E Case Rep Neurol Med. 2014; 2014:191305. Epub 2014 Aug 05. PMID: 25161784. Abstract
New data confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity (NEDA)' based on four key measures of MS Novartis, 12 Sep 2014 Accessed on 16 Sep 2014 from http://www.novartis.com/newsroom/media-releases/en/2014/1855482.shtml.
Sustained low rate of brain volume loss under long-term fingolimod treatment in relapsing multiple sclerosis: results from the LONGTERMS study Radue E, Barkhof F, Cohen J, Gottschalk R, Zhang Y, Cappiello L, von Rosenstiel P, Kappos L, 2014 Joint ACTRIMS-ECTRIMS Meeting Abstracts Accessed on 16 Sep 2014 from http://www.professionalabstracts.com/msboston2014/planner/index.php?go=abstract&action=abstract_show&absno=1346&MSBOSTON2014=ih470c52em90irurpkbgmjghjcr2luno. Abstract P439
Gilenya® data confirm reducing brain shrinkage matters for people with MS due to its association with long-term disability progression Novartis, 10 Sep 2014 Accessed on 16 Sep 2014 from http://www.novartis.com/newsroom/media-releases/en/2014/1854831.shtml.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance. Castro-Rojas C, Deason K, Hussain RZ, Hayardeny L, Cravens PC, Yarovinsky F, Eagar TN, Arellano B, Stüve O J Neuroimmunol. 2014 Sep 2. PMID: 25227585. Abstract
Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study. Gajofatto A, Bianchi M R, Deotto L, Benedetti M D Eur Neurol. 2014 Sep 6; 72(3-4):173-180. Epub 2014 Sep 06. PMID: 25226868. Abstract
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation. Yagi Y, Nakamura Y, Kitahara K, Harada T, Kato K, Ninomiya T, Cao X, Ohara H, Izumi-Nakaseko H, Suzuki K, et al. Toxicol Appl Pharmacol. 2014 Sep 16. PMID: 25223691. Abstract
FTY720 is neuroprotective after cuprizone-induced central nervous system demyelination. Slowik A, Schmidt T, Beyer C, Amor S, Clarner T, Kipp M Br J Pharmacol. 2014 Sep 14. PMID: 25220526. Abstract
The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis. Fragoso Y D, Arruda C C, Arruda W O, Brooks J B B, Damasceno A, de Damasceno C A A, Finkelsztejn A, Finkelsztejn J, da Gama P D, Giacomo M C B, et al. Arq Neuropsiquiatr. 2014 Sep; 72(9):712-4. PMID: 25252236. Abstract
Efficacy and Safety of Fingolimod in Hispanic Patients with Multiple Sclerosis: Pooled Clinical Trial Analyses. Chinea Martinez AR, Correale J, Coyle PK, Meng X, Tenenbaum N Adv Ther. 2014 Sep 23. Epub 2014 Sep 23. PMID: 25245812. Abstract
PML in MS Patients Making Natalizumab-to-Fingolimod Switch Jeffrey S, Medscape, 25 Sep 2014 Accessed on 30 Sep 2014 from http://www.medscape.com/viewarticle/832307.
Experience with Fingolimod in Clinical Practice. Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D Int J Neurosci. 2014 Oct 1:1-24. PMID: 25271798. Abstract
Relapses in patients treated with fingolimod after previous exposure to natalizumab. Comi G, Gold R, Dahlke F, Sinha A, von Rosenstiel P, Tomic D, Kappos L Mult Scler. 2014 Sep 25. PMID: 25257618. Abstract
Individual variation of human sphingosine 1-phosphate receptor 1 coding sequence leads to heterogeneity in receptor function and drug interactions. Obinata H, Gutkind S, Stitham J, Okuno T, Yokomizo T, Hwa J, Hla T J Lipid Res. 2014 Oct 7. PMID: 25293589. Abstract
Novartis MS pill heads stream of SMC approvals McKee S, PharmaTimes, 13 Oct 2014 Accessed on 21 Oct 2014 from http://www.pharmatimes.com/Article/14-10-13/Novartis_MS_pill_heads_stream_of_SMC_approvals.aspx.
Multiple sclerosis reactivation postfingolimod cessation: Is it IRIS? Alroughani R, Almulla A, Lamdhade S, Thussu A BMJ Case Rep. 2014; 2014. PMID: 25320259. Abstract
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis. Zhang X, Hay JW, Niu X CNS Drugs. 2014 Oct 19. PMID: 25326785. Abstract
Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia. Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung H-P, Olsson T, Kieseier BC Neurology. 2014 Oct 31. PMID: 25361781. Abstract
Compositional Changes of B and T Cell Subtypes during Fingolimod Treatment in Multiple Sclerosis Patients: A 12-Month Follow-Up Study. Claes N, Dhaeze T, Fraussen J, Broux B, Van Wijmeersch B, Stinissen P, Hupperts R, Hellings N, Somers V PLoS One. 2014; 9(10):e111115. Epub 2014 Oct 31. PMID: 25360562. Abstract
Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab. Bianco A, Patanella A K, Nociti V, Marti A, Frisullo G, Plantone D, De Fino C, Fetta A, Batocchi A P, Rossini P M, et al. Eur Neurol. 2014 Nov 7; 73(1-2):57-65. Epub 2014 Nov 07. PMID: 25402749. Abstract
Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients. Chiarini M, Sottini A, Bertoli D, Serana F, Caimi L, Rasia S, Capra R, Imberti L Mult Scler. 2014 Nov 12. PMID: 25392322. Abstract
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial. Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, et al. BMC Neurol. 2014 Nov 26; 14(1):220. Epub 2014 Nov 26. PMID: 25424122. Abstract
Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden. O'Day K, Meyer K, Stafkey-Mailey D, Watson C J Med Econ. 2014 Nov 25:1-22. PMID: 25422991. Abstract
Varicella-Zoster Virus Infections in Patients Treated With Fingolimod: Risk Assessment and Consensus Recommendations for Management. Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, Gershon A, Gershon M, Levin MJ, Bezuidenhoudt M, et al. JAMA Neurol. 2014 Nov 24. PMID: 25419615. Abstract
Editors' Pick No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G Adv Ther. 2014 Nov; 31(11):1134-54. Epub 2014 Nov 21. PMID: 25414048. Abstract
Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients. Muls N, Dang H A, Sindic CJM, van Pesch V PLoS One. 2014; 9(11):e113025. Epub 2014 Nov 20. PMID: 25411844. Abstract
Novartis provides update on fingolimod Phase III trial in primary progressive MS (PPMS) Novartis, 1 Dec 2014 Accessed on 2 Dec 2014 from http://www.novartis.com/newsroom/media-releases/en/2014/1875463.shtml.
Hypothyroidism in multiple sclerosis patient during fingolimod treatment. Flores J, Rito Y, Torres G, Jung H, Treviño-Frenk I, Corona T J Neurol Sci. 2014 Nov 13. PMID: 25491264. Abstract
Regulation of dimethyl-fumarate toxicity by proteasome inhibitors. Booth L, Cruickshanks N, Tavallai S, Roberts JL, Peery M, Poklepovic A, Dent P Cancer Biol Ther. 2014 Sep 24. PMID: 25482938. Abstract
PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation. Killestein J, Vennegoor A, van Golde AEL, Bourez RLJH, Wijlens MLB, Wattjes MP Case Rep Neurol Med. 2014; 2014:307872. Epub 2014 Nov 23. PMID: 25506447. Abstract
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis. Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, Izquierdo G, Rozsa C, Grammond P, Alroughani R, et al. Ann Neurol. 2014 Dec 27. PMID: 25546031. Abstract
Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS. Meng X, Chin PS, Hashmonay R, Zahur Islam M, Cutter G Contemp Clin Trials. 2014 Dec 26. PMID: 25545026. Abstract
Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis. Haas J, Schwarz A, Korporal-Kunke M, Jarius S, Wiendl H, Kieseier BC, Wildemann B Mult Scler. 2015 Jan 12. PMID: 25583847. Abstract
In vivo Positron Emission Tomography Imaging Demonstrates Diminished Microglial Activation after Fingolimod Treatment in an Animal Model of Multiple Sclerosis. Airas L, Dickens A, Elo P, Marjamäki P M, Johansson J, Eskola O, Jones P, Trigg W, Solin O, Haaparanta-Solin M, et al. J Nucl Med. 2015 Jan 8. PMID: 25572093. Abstract
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome. Signoriello E, Sagliocchi A, Fratta M, Lus G Acta Neurol Scand. 2015 Feb; 131(2):140-3. PMID: 25622658. Abstract
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis. Kappos L, Mehling M, Arroyo R, Izquierdo G, Selmaj K, Curovic-Perisic V, Keil A, Bijarnia M, Singh A, von Rosenstiel P Neurology. 2015 Jan 30. PMID: 25636714. Abstract
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. Radue E-W, Barkhof F, Kappos L, Sprenger T, Häring DA, de Vera A, von Rosenstiel P, Bright JR, Francis G, Cohen JA Neurology. 2015 Jan 28. PMID: 25632085. Abstract
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, et al. JAMA Neurol. 2015 Feb 9:1-10. PMID: 25665031. Abstract
Fingolimod effect on brain volume loss independently contributes to its effect on disability. Sormani M, De Stefano N, Francis G, Sprenger T, Chin P, Radue E, Kappos L Mult Scler. 2015 Feb 6. PMID: 25662353. Abstract
Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kümpfel T, Buck D, Hohlfeld R, Berthele A, Hemmer B Neurology. 2011 Apr 5; 76(14):1214-21. PMID: 21464424. Abstract
Fingolimod treatment promotes proliferation and differentiation of oligodendrocyte progenitor cells in mice with experimental autoimmune encephalomyelitis. Zhang J, Zhang Z G, Li Y, Ding X, Shang X, Lu M, Elias SB, Chopp M Neurobiol Dis. 2015 Feb 11; 76:57-66. PMID: 25680941. Abstract
Paroxysmal dysarthria-ataxia syndrome resolving after fingolimod treatment. Rossi S, Studer V, Motta C, Centonze D J Neurol Sci. 2015 Jan 28. PMID: 25676590. Abstract
FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis. Luessi F, Kraus S, Trinschek B, Lerch S, Ploen R, Paterka M, Roberg T, Poisa-Beiro L, Klotz L, Wiendl H, et al. Mult Scler. 2015 Mar 2. PMID: 25732840. Abstract
Subcellular distribution of FTY720 and FTY720-phosphate in immune cells - another aspect of Fingolimod action relevant for therapeutic application. Schröder M, Arlt O, Schmidt H, Huwiler A, Angioni C, Pfeilschifter JM, Schwiebs A, Radeke HH Biol Chem. 2015 Jan 14. PMID: 25720062. Abstract
Gilenya Safety Update Novartis, 16 Feb 2015 Accessed on 10 Mar 2015 from http://www.novartis.com/newsroom/product-related-info-center/gilenya-safety-update.shtml.
Fingolimod treatment promotes regulatory phenotype and function of B cells. Grützke B, Hucke S, Gross CC, Herold MVB, Posevitz-Fejfar A, Wildemann BT, Kieseier BC, Dehmel T, Wiendl H, Klotz L Ann Clin Transl Neurol. 2015 Feb; 2(2):119-30. Epub 2015 Jan 16. PMID: 25750917. Abstract
Insight into the conformational polymorph transformation of a block-buster multiple sclerosis drug fingolimod hydrochloride (FTY 720). Wang J-R, Li S, Zhu B, Mei X J Pharm Biomed Anal. 2015 Feb 19; 109C:45-51. PMID: 25746505. Abstract
Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis. Nishihara H, Shimizu F, Sano Y, Takeshita Y, Maeda T, Abe M, Koga M, Kanda T PLoS One. 2015; 10(3):e0121488. Epub 2015 Mar 16. PMID: 25774903. Abstract
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis. Kuhle J, Disanto G, Lorscheider J, Stites T, Chen Y, Dahlke F, Francis G, Shrinivasan A, Radue E-W, Giovannoni G, et al. Neurology. 2015 Mar 25. PMID: 25809304. Abstract
Editors' Pick Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Kappos L, O'Connor P, Radue E-W, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, et al. Neurology. 2015 Mar 20. Epub 1969 Dec 31. PMID: 25795646. Abstract
A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis. Lindå H, von Heijne A Front Neurol. 2015; 6:39. Epub 2015 Mar 04. PMID: 25788891. Abstract
Ventricular tachycardia on chronic fingolimod treatment for multiple sclerosis. Castillo-Trivino T, Lopetegui I, Alarcón-Duque J A, de Munain A L, Olascoaga J J Neurol Neurosurg Psychiatry. 2015 Apr 2. PMID: 25835036. Abstract
The effect of the sphingosine-1-phosphate analogue FTY720 on atrioventricular nodal tissue. Egom EE, Kruzliak P, Rotrekl V, Lei M J Cell Mol Med. 2015 Apr 13. PMID: 25864579. Abstract
Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients Novartis, 21 Apr 2015 Accessed on 21 Apr 2015 from http://www.novartis.com/newsroom/media-releases/en/2015/1912676.shtml.
Consistent reduction in the annualized rate of brain volume loss across phase 3 core and extension trials of fingolimod in relapsing multiple sclerosis. Radue E, Sprenger T, Chin P, Meier DP, Sfikas N, Barkhof F Mult Scler Relat Disord. 2014 Nov; 3(6):750-1. Epub 2014 Nov 21. PMID: 25891586. Abstract
Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing-Remitting Multipl Khatri BO, Pelletier J, Kappos L, Hartung H-P, Comi G, Barkhof F, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, et al. Mult Scler Relat Disord. 2014 May; 3(3):355-63. Epub 2013 Dec 12. PMID: 25876473. Abstract
Efficacy of lower fingolimod doses in the treatment of MS. Yamout B, Zeineddine MM, Khoury SJ Mult Scler Relat Disord. 2014 Nov; 3(6):758. Epub 2014 Nov 21. PMID: 25891604. Abstract
Good cardiac safety in patients with relapsing remitting multiple sclerosis upon first fingolimod dose. Limmroth V, Hoyer S, Schmidt S, Lang M, Ziemssen T Mult Scler Relat Disord. 2014 Nov; 3(6):754. Epub 2014 Nov 21. PMID: 25891594. Abstract
Categorical change in T2 lesion volume and clinical outcomes in the Phase III FREEDOMS and its extension study, evaluating fingolimod in patients with relapsing-remitting multiple sclerosis. Jeffery D, Cantogno EVD, Meier DP, Meinel M, Chin P, Shamim A Mult Scler Relat Disord. 2014 Nov; 3(6):752-3. Epub 2014 Nov 21. PMID: 25891591. Abstract
Long-term safety of fingolimod: Interim evaluation of data from the longterms trial. Rosenstiel PV, Gottschalk R, Cappiello L, Zhang Y, Said M, Kappos L Mult Scler Relat Disord. 2014 Nov; 3(6):752. Epub 2014 Nov 21. PMID: 25891590. Abstract
PANGAEA: Post-authorization Noninterventional German Safety Study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study. Ziemssen T, Diaz-Lorente M, Abdelkader M, Cornelissen C Mult Scler Relat Disord. 2014 Nov; 3(6):751. Epub 2014 Nov 21. PMID: 25891587. Abstract
Fingolimod (Gilenya) may improve the chances of conception in women with multiple sclerosis (MS) associated with secondary infertlity. Inshasi J, Almadani A, Alrukn S, Alboudi A Mult Scler Relat Disord. 2014 Nov; 3(6):749-50. Epub 2014 Nov 21. PMID: 25891583. Abstract
Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod. Tully T, Barkley A, Silber E Neurology. 2015 Apr 15. PMID: 25878178. Abstract
Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Kappos L, Cohen J, Collins W, de Vera A, Zhang-Auberson L, Ritter S, von Rosenstiel P, Francis G Mult Scler Relat Disord. 2014 Jul; 3(4):494-504. Epub 2014 Mar 25. PMID: 25877062. Abstract
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study. Kremenchutzky M, O'Connor P, Hohlfeld R, Zhang-Auberson L, von Rosenstiel P, Meng X, Grinspan A, Hashmonay R, Kappos L Mult Scler Relat Disord. 2014 May; 3(3):341-9. Epub 2013 Nov 05. PMID: 25876471. Abstract
Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis. Frisell T, Forsberg L, Nordin N, Kiesel C, Alfredsson L, Askling J, Hillert J, Olsson T, Piehl F Mult Scler. 2015 Apr 28. PMID: 25921036. Abstract
Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod. Song Z-Y, Yamasaki R, Kawano Y, Sato S, Masaki K, Yoshimura S, Matsuse D, Murai H, Matsushita T, Kira J-I PLoS One. 2014; 10(4):e0124923. Epub 2015 Apr 28. PMID: 25919001. Abstract
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation. Berger B, Baumgartner A, Rauer S, Mader I, Luetzen N, Farenkopf U, Stich O J Neuroimmunol. 2015 May 15; 282:118-22. Epub 2015 Apr 07. PMID: 25903738. Abstract
Long term cardiac safety and tolerability of Fingolimod in Multiple Sclerosis: A post-marketing study. Paolicelli D, Manni A, Direnzo V, D'Onghia M, Tortorella C, Zoccolella S, Trojano M J Clin Pharmacol. 2015 Apr 23. PMID: 25903516. Abstract
VZV encephalitis that developed in an immunized patient during fingolimod therapy. Issa NP, Hentati A Neurology. 2015 Jan 6; 84(1):99-100. Epub 2014 Nov 21. PMID: 25416038. Abstract
FTY720 attenuates excitotoxicity and neuroinflammation. Cipriani R, Chara J C, Rodríguez-Antigüedad A, Matute C J Neuroinflammation. 2015; 12(1):86. Epub 2015 May 08. PMID: 25953296. Abstract
Postoperative cystoid macular oedema in a patient on fingolimod. Fan Gaskin J C-C, Coote M BMJ Case Rep. 2015; 2015. PMID: 25969500. Abstract
Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors. Bermel RA, Hashmonay R, Meng X, Randhawa S, von Rosenstiel P, Sfikas N, Kantor D Mult Scler Relat Disord. 2015 May; 4(3):273-80. Epub 2015 Apr 13. PMID: 26008945. Abstract
Fingolimod Prescribed for the Treatment of Multiple Sclerosis in Patients Younger than Age 18 Years. Fragoso Y D, Alves-Leon S V, Barreira A A, Callegaro D, Ferreira M L B, Finkelsztejn A, Gomes S, Goncalves M V M, Moraes Machado M I, Marques V D, et al. Pediatr Neurol. 2015 Apr 2. PMID: 26026897. Abstract
Editors' Pick Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS. Kappos L, Radue E-W, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung H-P, Derfuss T, Naegelin Y, et al. Neurology. 2015 May 29. Epub 1969 Dec 31. PMID: 26024899. Abstract
Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Maruszczak MJ, Montgomery SM, Griffiths MJS, Bergvall N, Adlard N J Med Econ. 2015 Jun 9:1-24. PMID: 26055952. Abstract
Fingolimod effects on left ventricular function in multiple sclerosis. Racca V, Di Rienzo M, Cavarretta R, Toccafondi A, Vaini E, Ferratini M, Rovaris M Mult Scler. 2015 Jun 3. PMID: 26041795. Abstract
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer. Hait NC, Avni D, Yamada A, Nagahashi M, Aoyagi T, Aoki H, Dumur CI, Zelenko Z, Gallagher EJ, Leroith D, et al. Oncogenesis. 2015; 4:e156. PMID: 26053034. Abstract
Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor). Klotz L, Grützke B, Eveslage M, Deppe M, Gross CC, Kirstein L, Posevitz-Fejfar A, Schneider-Hohendorf T, Schwab N, Meuth SG, et al. BMC Neurol. 2015; 15:96. Epub 2015 Jun 23. PMID: 26099927. Abstract
The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. Ziemssen T, Kern R, Cornelissen C BMC Neurol. 2015; 15:93. Epub 2015 Jun 18. PMID: 26084334. Abstract
Effects of Three Months Fingolimod Therapy on Heart Rate. Simula S, Laitinen T, Laitinen TM, Tarkiainen T, Hartikainen JEK, Hartikainen P J Neuroimmune Pharmacol. 2015 Jun 20. Epub 2015 Jun 20. PMID: 26092537. Abstract
Balò's concentric sclerosis: still to be considered as a variant of multiple sclerosis? Pietroboni AM, Arighi A, De Riz MA, Ghezzi L, Calvi A, Avignone S, Scola E, Galimberti D, Triulzi F, Scarpini E Neurol Sci. 2015 Jun 25. Epub 2015 Jun 25. PMID: 26109007. Abstract
Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Cohen JA, Khatri B, Barkhof F, Comi G, Hartung H-P, Montalban X, Pelletier J, Stites T, Ritter S, von Rosenstiel P, et al. J Neurol Neurosurg Psychiatry. 2015 Jun 25. PMID: 26111826. Abstract
Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Derfuss T, Bergvall NK, Sfikas N, Tomic DL Curr Med Res Opin. 2015 Jun 29:1-16. PMID: 26121423. Abstract
Central Autonomic Dysfunction Delays Recovery of Fingolimod Induced Heart Rate Slowing. Hilz MJ, Intravooth T, Moeller S, Wang R, Lee D-H, Koehn J, Linker RA PLoS One. 2015; 10(7):e0132139. Epub 2015 Jul 06. PMID: 26147106. Abstract
Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720. Fujiwara M, Anstadt EJ, Khanna KM, Clark RB Clin Immunol. 2015 Mar 28; 158(1):103-113. PMID: 25829233. Abstract
A Multiple Sclerosis-Associated Variant of CBLB Links Genetic Risk with Type I IFN Function. Stürner K H, Borgmeyer U, Schulze C, Pless O, Martin R J Immunol. 2014 Sep 26. PMID: 25261476. Abstract
Antidepressant activity of fingolimod in mice. Di Nuzzo L, Orlando R, Tognoli C, Di Pietro P, Bertini G, Miele J, Bucci D, Motolese M, Scaccianoce S, Caruso A, et al. Pharmacol Res Perspect. 2015 Jun; 3(3):e00135. Epub 2015 May 24. PMID: 26171219. Abstract
IL-17-Producing Vγ4+ γδ T Cells Require Sphingosine 1-Phosphate Receptor 1 for Their Egress from the Lymph Nodes under Homeostatic and Inflammatory Conditions. Maeda Y, Seki N, Kataoka H, Takemoto K, Utsumi H, Fukunari A, Sugahara K, Chiba K J Immunol. 2015 Jul 13. PMID: 26170380. Abstract
Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study. Ordoñez-Boschetti L, Rey R, Cruz A, Sinha A, Reynolds T, Frider N, Alvarenga R Adv Ther. 2015 Jul; 32(7):626-35. Epub 2015 Jul 14. PMID: 26170105. Abstract
Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Miguez A, García-Díaz Barriga G, Brito V, Straccia M, Giralt A, Ginés S, Canals JM, Alberch J Hum Mol Genet. 2015 Jun 10. Epub 2015 Jun 10. PMID: 26063761. Abstract
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Warrender-Sparkes M, Spelman T, Izquierdo G, Trojano M, Lugaresi A, Grand'maison F, Havrdova E, Horakova D, Boz C, Oreja-Guevara C, et al. Mult Scler. 2015 Jul 21. PMID: 26199347. Abstract
Fingolimod does not enhance cerebellar remyelination in the cuprizone model. Alme M N, Nystad AE, Bø L, Myhr K-M, Vedeler CA, Wergeland S, Torkildsen Ø J Neuroimmunol. 2015 Aug 15; 285:180-6. Epub 2015 Jun 19. PMID: 26198937. Abstract
Safety and efficacy of reduced fingolimod dosage treatment. Yamout BI, Zeineddine MM, Sawaya RA, Khoury SJ J Neuroimmunol. 2015 Aug 15; 285:13-5. Epub 2015 May 15. PMID: 26198913. Abstract
Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli? Spampinato SF, Obermeier B, Cotleur A, Love A, Takeshita Y, Sano Y, Kanda T, Ransohoff RM PLoS One. 2015; 10(7):e0133392. Epub 2015 Jul 21. PMID: 26197437. Abstract
Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis. Samaraweera A P, Cohen SN, Akay EM, Evangelou N Mult Scler. 2015 Jul 28. Epub 2015 Jul 28. PMID: 26219664. Abstract
FDA Drug Safety Communication: FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs US Food and Drug Administration, 4 Aug 2015 Accessed on 11 Aug 2015 from http://www.fda.gov/Drugs/DrugSafety/ucm456919.htm.
Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study. Totaro R, Di Carmine C, Costantino G, Fantozzi R, Bellantonio P, Fuiani A, Mundi C, Ruggieri S, Marini C, Carolei A Mult Scler Int. 2015; 2015:763418. Epub 2015 Jul 22. PMID: 26266049. Abstract
First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, et al. Mult Scler Relat Disord. 2014 Sep; 3(5):620-8. Epub 2014 Jul 03. PMID: 26265274. Abstract
Editors' Pick Outcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis. Fox E, Edwards K, Burch G, Wynn DR, Laganke C, Crayton H, Hunter SF, Huffman C, Kim E, Pestreich L, et al. Mult Scler Relat Disord. 2014 Sep; 3(5):607-19. Epub 2014 Jul 04. PMID: 26265273. Abstract
Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple sclerosis three months after childbirth. Kraemer M, Weber R, Herold M, Berlit P Mult Scler. 2015 Aug 17. PMID: 26283695. Abstract
Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis. Pfender N, Jelcic I, Linnebank M, Schwarz U, Martin R Neurology. 2015 Jun 9; 84(23):2377-8. Epub 2015 May 08. PMID: 25957334. Abstract
Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod. Masera S, Chiavazza C, Mattioda A, Superti G, Beggiato E, Crosasso P, Broganelli P, Pinessi L, Cavalla P Mult Scler. 2014 Oct; 20(12):1666-7. Epub 2014 Mar 06. PMID: 24603883. Abstract
Another Case of PML with Gilenya Reported by Novartis Ciccone A, Neurology Advisor, 19 Aug 2015 Accessed on 25 Aug 2015 from http://www.neurologyadvisor.com/neuromuscular-disorders/gilenya-novartis-multiple-sclerosis-pml/article/433640/.
Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod. Huang D Neurology. 2015 Aug 19. PMID: 26291283. Abstract
FTY720 inhibits tubulointerstitial inflammation in albumin overload-induced nephropathy of rats via the Sphk1 pathway. Xu M, Liu D, Ding L-hong, Ma K-ling, Wu M, Lv L-li, Wen Y, Liu H, Tang R-ning, Liu B-cheng Acta Pharmacol Sin. 2014 Dec; 35(12):1537-45. Epub 2014 Nov 17. PMID: 25399649. Abstract
Disease Activity during the First Year Predicts Clinical Long-Term Outcomes in Patients with Multiple Sclerosis: Fingolimod Treatment Benefit Repovic P, Burton E, Meng X, Meier D P, Barkhof F, Consortium of Multiple Sclerosis Centers Annual Meeting Presentations, 29 May 2015 Accessed on 8 Sep 2015 from https://cmsc.confex.com/cmsc/2015/webprogram/.
Fingolimod-Associated Peripheral Vascular Adverse Effects. Russo M, Guarneri C, Mazzon E, Sessa E, Bramanti P, Calabrò R S Mayo Clin Proc. 2015 Sep 5. PMID: 26349949. Abstract
Emerging tumefactive MS after switching therapy from interferon-beta to fingolimod: A case report. Harirchian M, Taalimi A, Siroos B Mult Scler Relat Disord. 2015 Sep; 4(5):400-2. PMID: 26346786. Abstract
Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. Montalban X, Comi G, Antel J, O'Connor P, de Vera A, Cremer M, Sfikas N, von Rosenstiel P, Kappos L J Neurol. 2015 Sep 4. Epub 2015 Sep 04. PMID: 26338810. Abstract
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore G B, Marrosu M G, et al. Brain. 2015 Sep 11. PMID: 26362907. Abstract
Effect of fingolimod on cardiac autonomic regulation in patients with multiple sclerosis. Simula S, Laitinen T, Laitinen TM, Tarkiainen T, Hartikainen P, Hartikainen JEK Mult Scler. 2015 Sep 11. PMID: 26362903. Abstract
Prediction of disability progression in fingolimod-treated patients. Lattanzi S, Danni M, Cerqua R, Taffi R, Provinciali L, Silvestrini M J Neurol Sci. 2015 Sep 6. PMID: 26362335. Abstract
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Tramacere I, Giovane C D, Salanti G, D'Amico R, Filippini G Cochrane Database Syst Rev. 2015 Sep 18; 9:CD011381. PMID: 26384035. Abstract
Fingolimod induces neuroprotective factors in human astrocytes. Hoffmann FS, Hofereiter J, Rübsamen H, Melms J, Schwarz S, Faber H, Weber P, Pütz B, Loleit V, Weber F, et al. J Neuroinflammation. 2015; 12(1):184. Epub 2015 Sep 30. PMID: 26419927. Abstract
Acute Lymphoblastic Leukemia in a Man Treated With Fingolimod for Relapsing Multiple Sclerosis. Cohan S, Godwin J, Gaedeke L J Investig Med High Impact Case Rep. 2015 Jan-Mar; 3(1):2324709615575551. Epub 2015 Mar 09. PMID: 26425635. Abstract
Fingolimod May Protect Neurons from Degeneration Blum K, MedPage Today, 5 Oct 2015 Accessed on 13 Oct 2015 from http://www.medpagetoday.com/MeetingCoverage/ANA/53913.
Similar Effects Seen for Fingolimod, Placebo in Primary Progressive Multiple Sclerosis Neurology Advisor, 7 Oct 2015 Accessed on 13 Oct 2015 from http://www.neurologyadvisor.com/ectrims-2015/fingolimod-effect-primary-progressive-multiple-sclerosis/article/443534/.
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years Novartis, 8 Oct 2015 Accessed on 13 Oct 2015 from https://www.novartis.com/news/media-releases/long-term-efficacy-gilenya®-reinforced-new-no-evidence-disease-activity-neda-4.
Cryptococcal Meningoencephalitis in a Patient With Multiple Sclerosis Treated With Fingolimod. Achtnichts L, Obreja O, Conen A, Fux CA, Nedeltchev K JAMA Neurol. 2015 Oct 1; 72(10):1203-5. PMID: 26457631. Abstract
Fingolimod protects against neonatal white matter damage and long-term cognitive deficits caused by hyperoxia. Serdar M, Herz J, Kempe K, Lumpe K, Reinboth BS, Sizonenko SV, Hou X, Herrmann R, Hadamitzky M, Heumann R, et al. Brain Behav Immun. 2015 Oct 12. PMID: 26456693. Abstract
The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. Oommen VV, Tauhid S, Healy BC, Chua AS, Malik MT, Diaz-Cruz C, Dupuy SL, Weiner HL, Chitnis T, Bakshi R J Neuroimaging. 2015 Oct 8. PMID: 26445919. Abstract
Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report. Ueda N, Saida K BMC Ophthalmol. 2015; 15(1):135. Epub 2015 Oct 19. PMID: 26481728. Abstract
Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720). Yazdi A, Baharvand H, Javan M Neuroscience. 2015 Dec 17; 311:34-44. Epub 2015 Oct 17. PMID: 26475743. Abstract
FTY720 (Fingolimod) sensitizes hepatocellular carcinoma cells to sorafenib-mediated cytotoxicity. Ahmed D, de Verdier PJ, Ryk C, Lunqe O, Stål P, Flygare J Pharmacol Res Perspect. 2015 Oct; 3(5):e00171. Epub 2015 Aug 19. PMID: 26516583. Abstract
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment. Faissner S, Hoepner R, Lukas C, Chan A, Gold R, Ellrichmann G Ther Adv Neurol Disord. 2015 Sep; 8(5):233-8. PMID: 26557898. Abstract
Superficial spreading malignant melanoma in a patient on fingolimod therapy for multiple sclerosis. Haebich G, Mughal A, Tofazzal N Clin Exp Dermatol. 2015 Nov 18. PMID: 26577239. Abstract
Effect of vitamin D on MS activity by disease-modifying therapy class. Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz B, Chitnis T Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e167. Epub 2015 Oct 29. PMID: 26568968. Abstract
Myeloid cells as target of fingolimod action in multiple sclerosis. Di Dario M, Colombo E, Govi C, De Feo D, Messina M J, Romeo M, Sangalli F, Moiola L, Rodegher M, Martino G, et al. Neurol Neuroimmunol Neuroinflamm. 2015 Dec; 2(6):e157. Epub 2015 Nov 04. PMID: 26587553. Abstract
Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. Kappos L, De Stefano N, Freedman MS, Cree BAC, Radue E-W, Sprenger T, Sormani M P, Smith T, Häring DA, Meier D P, et al. Mult Scler. 2015 Nov 19. PMID: 26585439. Abstract
Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East. Yamout BI, Zeineddine MM, Tamim H, Khoury SJ J Neuroimmunol. 2015 Dec 15; 289:93-7. Epub 2015 Oct 26. PMID: 26616877. Abstract
Influence of fingolimod on basic lymphocyte subsets frequencies in the peripheral blood of multiple sclerosis patients - preliminary study. Rudnicka J, Czerwiec M, Grywalska E, Siwicka-Gieroba D, Walankiewicz M, Grafka A, Zgurski M, Surdacka A, Bartosik-Psujek H, Roliński J Cent Eur J Immunol. 2015; 40(3):354-9. Epub 2015 Oct 15. PMID: 26648781. Abstract
Onset of clinical and MRI efficacy occurs early after fingolimod treatment initiation in relapsing multiple sclerosis. Kappos L, Radue E-W, Chin P, Ritter S, Tomic D, Lublin F J Neurol. 2015 Dec 8. Epub 2015 Dec 08. PMID: 26645392. Abstract
Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis. Braune S, Lang M, Bergmann A, NeuroTransData Study Group J Neurol. 2015 Dec 8. Epub 2015 Dec 08. PMID: 26645389. Abstract
Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice. Hou H, Cao R, Miao J, Sun Y, Liu X, Song X, Guo L Int Immunopharmacol. 2015 Nov 26. PMID: 26632437. Abstract
Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis. Jones AJ, Kaiser M, Avery VM Antimicrob Agents Chemother. 2015 Dec 14. PMID: 26666915. Abstract
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity. Luchtman D, Gollan R, Ellwardt E, Birkenstock J, Robohm K, Siffrin V, Zipp F J Neurochem. 2015 Dec 10. PMID: 26662167. Abstract
Ventricular arrhythmia in a male MS patient on fingolimod. van Pesch V, Marchandise S, Elsankari S, Sindic C Acta Neurol Belg. 2015 Mar; 115(1):77-9. Epub 2014 Apr 08. PMID: 24710722. Abstract
FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue. Xiao W, Xu G-T, Zhang J, Zhang J, Zhang Y, Ye W Exp Eye Res. 2015 Sep; 138:145-52. Epub 2015 Jul 14. PMID: 26187517. Abstract
New EMA Advice for PML Prevention With Fingolimod in MS Anderson P, Medscape, 18 Dec 2015 Accessed on 22 Dec 2015 from http://www.medscape.com/viewarticle/856208.
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. Mauskopf J, Fay M, Iyer R, Sarda S, Livingston T J Med Econ. 2015 Dec 26:1-36. PMID: 26707273. Abstract
Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis. de Bruin NMWJ, Schmitz K, Schiffmann S, Tafferner N, Schmidt M, Jordan H, Häußler A, Tegeder I, Geisslinger G, Parnham MJ Behav Brain Res. 2015 Dec 12. PMID: 26692368. Abstract
Fingolimod (FTY720-P) Does Not Stabilize the Blood-Brain Barrier under Inflammatory Conditions in an in Vitro Model. Schuhmann MK, Bittner S, Meuth SG, Kleinschnitz C, Fluri F Int J Mol Sci. 2015; 16(12):29454-66. PMID: 26690412. Abstract
Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes. Ottenlinger F, Schwiebs A, Pfarr K, Wagner A, Grüner S, Mayer C, Pfeilschifter JM, Radeke HH Eur J Immunol. 2015 Dec 18. PMID: 26683421. Abstract
Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. Mazzola M A, Raheja R, Murugaiyan G, Rajabi H, Kumar D, Pertel T, Regev K, Griffin R, Aly L, Kivisakk P, et al. J Neuroinflammation. 2015; 12(1):245. Epub 2015 Dec 30. PMID: 26714756. Abstract
Efficacy and Safety of Fingolimod in an Unselected Patient Population. Rasenack M, Rychen J, Andelova M, Naegelin Y, Stippich C, Kappos L, Lindberg RLP, Sprenger T, Derfuss T PLoS One. 2016; 11(1):e0146190. Epub 2016 Jan 06. PMID: 26734938. Abstract
Elevated Nuclear and Cytoplasmic FTY720-Phosphate in Mouse Embryonic Fibroblasts Suggests the Potential for Multiple Mechanisms in FTY720-Induced Neural Tube Defects. Gardner NM, Riley RT, Showker JL, Voss KA, Sachs AJ, Maddox JR, Gelineau-van Waes JB Toxicol Sci. 2015 Dec 29. PMID: 26719367. Abstract
Primary Cutaneous Cryptococcus in a Patient With Multiple Sclerosis Treated With Fingolimod. Forrestel AK, Modi BG, Longworth S, Wilck MB, Micheletti RG JAMA Neurol. 2016 Jan 11:1-2. PMID: 26751160. Abstract
Biointegrator announced that it has successfully launched Neskler® - a first generic of Gilenya® in Russia and EuroAsian Economic Union ChemRar, 11 Jan 2016 Accessed on 19 Jan 2016 from http://www.chemrar.ru/eng/press/press.php?ELEMENT_ID=20580.
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. Spelman T, Mekhael L, Burke T, Butzkueven H, Hodgkinson S, Havrdova E, Horakova D, Duquette P, Izquierdo G, Grand'maison F, et al. Eur J Neurol. 2016 Jan 19. PMID: 26782663. Abstract
Effects of fumarates on circulating and CNS myeloid cells in multiple sclerosis. Michell-Robinson MA, Moore CS, Healy LM, Osso LA, Zorko N, Grouza V, Touil H, Poliquin-Lasnier L, Trudelle A-M, Giacomini PS, et al. Ann Clin Transl Neurol. 2016 Jan; 3(1):27-41. Epub 2015 Dec 02. PMID: 26783548. Abstract
Fingolimod induces neurogenesis in adult mouse hippocampus and improves contextual fear memory. Efstathopoulos P, Kourgiantaki A, Karali K, Sidiropoulou K, Margioris AN, Gravanis A, Charalampopoulos I Transl Psychiatry. 2015; 5:e685. PMID: 26795749. Abstract
Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Barbin L, Rousseau C, Jousset N, Casey R, Debouverie M, Vukusic S, De Sèze J, Brassat D, Wiertlewski S, Brochet B, et al. Neurology. 2016 Jan 29. PMID: 26826205. Abstract
Editors' Pick Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, Weiner H, Lubetzki C, Hartung H-P, Montalban X, Uitdehaag B M, et al. Lancet. 2016 Jan 27. Epub 1969 Dec 31. PMID: 26827074. Abstract
The Sphingosine 1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Post-Infarction Left Ventricular Remodeling in a Porcine Model of Ischemia-Reperfusion. Santos-Gallego CG, Vahl TP, Goliasch G, Picatoste B, Arias T, Ishikawa K, Njerve IU, Sanz J, Narula J, Sengupta P, et al. Circulation. 2016 Jan 29. PMID: 26826180. Abstract
Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient. Artemiadis A, Nikolaou G, Kolokythopoulos D, Tegos N, Terentiou A, Triantafyllou N, Papanastasiou I Mult Scler. 2014 Nov 28. PMID: 25432949. Abstract
Extensive molluscum contagiosum virus infection in a young adult receiving fingolimod. Behle V, Wobser M, Goebeler M, Stoevesandt J Mult Scler. 2016 Feb 9. PMID: 26860987. Abstract
Effect of Fingolimod on Platelet Count Among Multiple Sclerosis Patients. Farrokhi M, Beni A A, Etemadifar M, Rezaei A, Rivard L, Zadeh A R, Sedaghat N, Ghadimi M Int J Prev Med. 2015; 6:125. Epub 2015 Dec 23. PMID: 26900439. Abstract
First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. DiMarco JP, O'Connor P, Cohen JA, Reder AT, Zhang-Auberson L, Tang D, Collins W, Kappos L Mult Scler Relat Disord. 2014 Sep; 3(5):629-38. Epub 2014 Jun 17. PMID: 26265275. Abstract
The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients. Mathias A, Perriard G, Canales M, Vuilleumier F, Perrotta G, Schluep M, Du Pasquier R Neurol Neuroimmunol Neuroinflamm. 2016 Apr; 3(2):e209. Epub 2016 Feb 10. PMID: 26913291. Abstract
FTY720 (Fingolimod) attenuates basal and sphingosine 1-phosphate-evoked thyroid cancer cell invasion. Kalhori V, Magnusson M, Asghar M Y, Pulli I, Törnquist K Endocr Relat Cancer. 2016 Mar 2. PMID: 26935838. Abstract
Plasma levels of endothelial and B-cell-derived microparticles are restored by fingolimod treatment in multiple sclerosis patients. Zinger A, Latham SL, Combes V, Byrne S, Barnett MH, Hawke S, Grau GE Mult Scler. 2016 Mar 1. PMID: 26931477. Abstract
Local delivery of FTY720 in PCL membrane improves SCI functional recovery by reducing reactive astrogliosis. Wang J, Wang J, Lu P, Cai Y, Wang Y, Hong L, Ren H, Heng B C, Liu H, Zhou J, et al. Biomaterials. 2015 Sep; 62:76-87. Epub 2015 May 15. PMID: 26036174. Abstract
Glioblastoma following treatment with fingolimod for relapsing-remitting multiple sclerosis. Sharim J, Tashjian R, Golzy N, Pouratian N J Clin Neurosci. 2016 Mar 9. PMID: 26970935. Abstract
Cost-Effectiveness of Treatments for Relapsing Remitting Multiple Sclerosis: A French Societal Perspective. Chevalier J, Chamoux C, Hammès F, Chicoye A PLoS One. 2016; 11(3):e0150703. Epub 2016 Mar 17. PMID: 26987055. Abstract
Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmeström C, Piehl F, Olsson T, Lycke J Mult Scler. 2016 Mar 21. PMID: 27003946. Abstract
Topical Application of Fingolimod Perturbs Cutaneous Inflammation. Sun WY, Dimasi DP, Pitman MR, Zhuang YZ, Heddle R, Pitson SM, Grimbaldeston MA, Bonder CS J Immunol. 2016 Mar 21. PMID: 27001955. Abstract
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod. Tanaka M Rinsho Shinkeigaku. 2016 Mar 24. PMID: 27010095. Abstract
Rituximab versus fingolimod after natalizumab in multiple sclerosis patients. Alping P, Frisell T, Novakova L, Islam-Jakobsson P, Salzer J, Björck A, Axelsson M, Malmeström C, Fink K, Lycke J, et al. Ann Neurol. 2016 Mar 31. PMID: 27038238. Abstract
Sphingosine-1-phosphate receptor inhibition prevents denervation-induced dendritic atrophy. Willems LM, Zahn N, Ferreirós N, Scholich K, Maggio N, Deller T, Vlachos A Acta Neuropathol Commun. 2016; 4(1):28. Epub 2016 Mar 31. PMID: 27036416. Abstract
Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab. Fragoso Y D, da Gama P D, Gomes S, Khouri J M N, da Matta A P C, Mendes M F, Stella C R A V Mult Scler Relat Disord. 2016 Mar; 6:64-5. Epub 2016 Jan 28. PMID: 27063625. Abstract
The effectiveness of fingolimod in a Portuguese real-world population. Correia I, Batista S, Marques IB, Sousa M, Ferreira R, Nunes C, Macário MC, Sousa L Mult Scler Relat Disord. 2016 Mar; 6:41-8. Epub 2016 Jan 12. PMID: 27063621. Abstract
Editors' Pick A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Koch-Henriksen N, Magyari M, Sellebjerg F, Sørensen P S Mult Scler. 2016 Apr 7. Epub 1969 Dec 31. PMID: 27055806. Abstract
Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis. Blumenfeld S, Staun-Ram E, Miller A J Autoimmun. 2016 Apr 4. PMID: 27055778. Abstract
Lymphomatoid papulosis type D in a fingolimod-treated multiple sclerosis patient. Matoula T, Nikolaou V, Marinos L, Katsavos S, Nasis G, Economidi A, Karampidou K, Stratigos A, Antoniou C Mult Scler. 2016 Apr 6. PMID: 27053634. Abstract
Interim Report Released on Real-World Safety of Fingolimod for Relapsing MS MPR, 17 Apr 2016 Accessed on 19 Apr 2016 from http://www.empr.com/aan-2016-multiple-sclerosis/interim-report-released-on-real-world-safety-of-fingolimod-for-relapsing-ms/article/487770/.
